Health & Fitness
Health and Fitness
Health and Fitness
Wed, August 22, 2012Tue, August 21, 2012Mon, August 20, 2012Sat, August 18, 2012Fri, August 17, 2012Thu, August 16, 2012Wed, August 15, 2012Tue, August 14, 2012Mon, August 13, 2012Fri, August 10, 2012Thu, August 9, 2012Wed, August 8, 2012Tue, August 7, 2012Mon, August 6, 2012Fri, August 3, 2012Thu, August 2, 2012Wed, August 1, 2012Tue, July 31, 2012Mon, July 30, 2012Isis Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
Published in Health and Fitness on Thursday, August 9th 2012 at 4:16 GMT by Market Wire
Isis Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference -- CARLSBAD, Calif., Aug. 9, 2012 /PRNewswire/ --
Isis Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
CARLSBAD, Calif., Aug. 9, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: [ ISIS ]), the leader in antisense therapeutics, today announced that management will present a company overview at the Canaccord Genuity 32nd Annual Growth Healthcare Conference on Thursday, August 16, 2012 at 11:00 a.m. ET in Boston.
A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, [ www.isispharm.com ]. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO™, in the United States and Europe following regulatory approval. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at [ www.isispharm.com ].
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2011 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc., its jointly owned subsidiary.
Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. KYNAMRO™ is a trademark of Genzyme Corporation.
SOURCE Isis Pharmaceuticals, Inc.
[ Back to top ]
RELATED LINKS
[ http://www.isispharm.com ]
